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Impairment of TrkB-PSD-95 Signaling in Angelman
Syndrome
Cong Cao1,2, Mengia S. Rioult-Pedotti1, Paolo Migani3, Crystal J. Yu1, Rakesh Tiwari4,
Keykavous Parang4, Mark R. Spaller5, Dennis J. Goebel6*, John Marshall1*
1 Department of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island, United States of America, 2 Institute of
Neuroscience, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou, China, 3 Dipartimento di Scienze della Vita e dell’Ambiente, Università
Politecnica delle Marche, Ancona, Italy, 4 Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island,
United States of America, 5 Norris Cotton Cancer Center and Department of Pharmacology and Toxicology, Dartmouth Medical School, Lebanon, New Hampshire, United
States of America, 6 Department of Anatomy and Cell Biology, Wayne State University, Detroit, Michigan, United States of America

Abstract
Angelman syndrome (AS) is a neurodevelopment disorder characterized by severe cognitive impairment and a high rate of
autism. AS is caused by disrupted neuronal expression of the maternally inherited Ube3A ubiquitin protein ligase, required
for the proteasomal degradation of proteins implicated in synaptic plasticity, such as the activity-regulated cytoskeletalassociated protein (Arc/Arg3.1). Mice deficient in maternal Ube3A express elevated levels of Arc in response to synaptic
activity, which coincides with severely impaired long-term potentiation (LTP) in the hippocampus and deficits in learning
behaviors. In this study, we sought to test whether elevated levels of Arc interfere with brain-derived neurotrophic factor
(BDNF) TrkB receptor signaling, which is known to be essential for both the induction and maintenance of LTP. We report
that TrkB signaling in the AS mouse is defective, and show that reduction of Arc expression to control levels rescues the
signaling deficits. Moreover, the association of the postsynaptic density protein PSD-95 with TrkB is critical for intact BDNF
signaling, and elevated levels of Arc were found to impede PSD-95/TrkB association. In Ube3A deficient mice, the BDNFinduced recruitment of PSD-95, as well as PLCc and Grb2-associated binder 1 (Gab1) with TrkB receptors was attenuated,
resulting in reduced activation of PLCc-a-calcium/calmodulin-dependent protein kinase II (CaMKII) and PI3K-Akt, but leaving
the extracellular signal-regulated kinase (Erk) pathway intact. A bridged cyclic peptide (CN2097), shown by nuclear magnetic
resonance (NMR) studies to uniquely bind the PDZ1 domain of PSD-95 with high affinity, decreased the interaction of Arc
with PSD-95 to restore BDNF-induced TrkB/PSD-95 complex formation, signaling, and facilitate the induction of LTP in AS
mice. We propose that the failure of TrkB receptor signaling at synapses in AS is directly linked to elevated levels of Arc
associated with PSD-95 and PSD-95 PDZ-ligands may represent a promising approach to reverse cognitive dysfunction.
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Ube3A ubiquitinates and degrades the immediate-early gene
Arc (activity-regulated cytoskeletal-associated protein) [10], whose
expression is required for LTP consolidation [11,12] and
experience-dependent plasticity [13–15]. Arc promotes AMPA
receptor (AMPAR) internalization [16] to reduce AMPARmediated synaptic transmission [17], and mediates AMPAR
clearance at weaker synapses [18]. Arc has been reported to
associate with postsynaptic density protein-95 (PSD-95) [19], the
prototypical PDZ (PSD-95/Discs large/zona occludens-1) postsynaptic protein [20,21], known to play a key role in the
endocytosis of synaptic AMPARs [22–24] and to regulate
AMPAR incorporation at synapses [25–28]. The PDZ domains
of PSD-95 bind the cytoplasmic tails of select NMDA and Kainate

Introduction
Angelman syndrome (AS) is a severe cognitive disorder caused
by loss of expression of the maternally inherited allele of the Ube3A
ubiquitin ligase gene [1,2]. As a result of imprinting, the paternal
Ube3A gene is silenced, such that the maternal allele is exclusively
active [3,4]. Prominent clinical characteristics include seizures,
ataxia, and mental retardation [5]. A mouse model null for
maternal Ube3a [6] showed impairment in long-term potentiation
(LTP) and learning [6]. Biochemically, the mice exhibited
dysregulation of a-calcium/calmodulin-dependent protein kinase
II (CaMKII) activity [7,8], required for certain forms of learning
[9].
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from hippocampal slices of AS and WT littermate male mice, 2–
4 mo of age, by stimulating Schaffer collaterals and recording
from the stratum radiatum of the CA1 area. LTP was considered
successful when the average EPSP slope showed an increase of at
least 20% lasting 55–60 min after induction. In WT mice, we
found that CN2097 significantly increased the LTP induction rate
under subthreshold conditions.
Thus, a single high frequency stimulation (16 HFS, 1 s at
100 Hz) did not induce LTP in the majority of WT slices tested;
with a mean fEPSP slope as a percentage of baseline of
107.964.8% (n = 11 of 14; Figure 1A). In contrast, applying two
HFS trains (26 HFS; 261 s at 100 Hz separated by 15 s)
significantly increased the induction rate of LTP (mean fEPSP
slope of 178.5615.8%, n = 6 of 10, p,0.001; Figure 1A).
Importantly, in the presence of CN2097 (2 mM), the LTP
induction rate of a single HFS was significantly increased,
resulting in LTP in 69% of the slices tested with a mean fEPSP
slope of 164.8625.0% (n = 11 of 16, p,0.05 compared to control
16 HFS; Figure 1A). This LTP was shown to be NMDA receptor
dependent, as it was blocked by APV, a competitive NMDA
receptor antagonist (n = 8, unpublished data). CN2097 alone did
not significantly affect baseline synaptic transmission (% fEPSP
slope: baseline 10060.002, CN2097 102.562.66, n = 7, p = 0.19;
Figure 1C, top). CN5135, a negative control compound where the
0 and 22 ring positions of CN2097 were substituted with alanine
residues to disrupt PDZ binding (Figure S1A), did not significantly
increase the LTP induction rate of a single HFS (108.165.0%,
n = 6 of 8, p = 0.5). These results suggest that in WT littermates of
AS mice CN2097 can reduce the threshold for LTP induction.
In AS hippocampal slices, deficits in LTP were reported to be
due to an alteration in the induction threshold, and LTP could be
rescued by increasing synaptic stimulation at 32uC [8]. Consistent
with previous studies [6–8,15], we were unable to induce LTP in
AS mice, using either a single (n = 5) or two sets of HFS (n = 7).
Similarly, applying three sets of HFS also did not induce LTP
when recorded at 30uC (36 HFS: 9764.6%, n = 8 of 10;
Figure 1B). However, in the presence of CN2097 (for 30 min
before LTP induction) the 36HFS protocol significantly increased
the LTP induction rate, with LTP being observed in 67% of AS
slices recorded with a mean fEPSP slope of 167.467% (n = 8 of 12,
p,0.0001; Figure 1B). CN2097 had no significant effect on fEPSP
slopes in AS slices (% fEPSP slope: baseline 10060.005, CN2097
100.865.39, n = 5, p = 0.45, Figure 1C, bottom) of evoked synaptic
responses.

Author Summary
Angelman syndrome (AS) is a debilitating neurological
disorder caused by a dysfunctional Ube3A gene. Most
children with AS exhibit developmental delay, movement
disorders, speech impairment, and often autistic features.
The Ube3A enzyme normally regulates the degradation of
the synaptic protein Arc, and in its absence the resulting
elevated levels of Arc weaken synaptic contacts, making it
difficult to generate long-term potentiation (LTP) and to
process and store memory. In this study, we show that
increased levels of Arc disrupt brain-derived neurotrophic
factor (BDNF) signaling through the TrkB receptor (which is
important for both the induction and maintenance of LTP).
We find that the association of the postsynaptic density
protein PSD-95 with TrkB is critical for intact BDNF
signaling, and that the high levels of Arc in AS interfere
with BDNF-induced recruitment of postsynaptic density
protein-95 (PSD-95) and other effectors to TrkB. By
disrupting the interaction between Arc and PSD-95 with
the novel cyclic peptidomimetic compound CN2097, we
were able to restore BDNF signaling and improve the
induction of LTP in a mouse model of AS. We propose that
the disruption of TrkB receptor signaling at synapses
contributes to the cognitive dysfunction that occurs in
Angelman syndrome.
receptor subunits [29,30] to assemble cell-signaling scaffolds
[31,32]. To investigate the function of PSD-95, we synthesized a
high affinity PSD-95 PDZ-domain peptidomimetic ligand,
CN2097. The design of CN2097 (R7-CC-YK[KTE(b-Ala)]V),
incorporates a lactam ring and a b-alanine linker that form unique
contacts outside the canonical PDZ binding pocket [33,34].
In the present study, we sought to test if the deficit in LTPinduction in AS mice might be the result of defective brain-derived
neurotrophic factor (BDNF) signaling. BDNF binding to the TrkB
receptor has been shown to promote the induction and
maintenance of LTP [35–39], and BDNF or TrkB deficient mice
exhibit a marked reduction in LTP [40–42]. We report that PSD95 association with TrkB is critical for intact BDNF signaling. In
AS hippocampal slices, the BDNF-induced association of PSD-95
with TrkB was reduced compared to wild type (WT), resulting in
attenuated PLCc (CaMKII and CREB) and PI3K (Akt-mTOR)
signaling, whereas MAPK (extracellular signal-regulated kinase
[Erk]) signaling was intact. In AS mice the elevated association of
Arc with PSD-95 is shown to interfere with the recruitment of
PSD-95 to TrkB. Treatment of AS hippocampal slices with
CN2097, the PSD-95 PDZ-domain peptidomimetic ligand,
increases the association of PSD-95 with TrkB to restore PLCc
and PI3K-Akt-mTOR signaling in AS mice, and to facilitate LTP.
Together, these data suggest drugs based on enhancing Trk-PSD95 interactions, such as CN2097, may provide a novel approach
for the treatment of AS and autism spectrum disorders.

AS Mice Exhibit Deficits in BDNF Signaling
The defects in LTP induction observed in AS mice are
reminiscent of those observed in BDNF and TrkB mutant mice
[40–42,46], which led to examine whether BDNF signaling was
compromised in AS mice. NMDA receptor activity promotes the
release of BDNF [47] to stimulate TrkB-PLCc-CaMKII/CaMKIV-CREB and PI3K-Akt signaling pathways [48,49]. BDNFTrkB signaling increases the delivery of PSD-95 [50] and AMPAR
subunits to synapses [51,52], and is reported to play a role in
transsynaptic coordination [53,54].
To determine whether AS mice exhibit defects in BDNF
signaling, we performed western blot analysis probed with
phospho-specific antibodies to assay Erk, Akt, and CaMKII
activity, in age-matched WT- and AS-coronal brain slices
comprising the hippocampus and cortex [36]. In terms of Erk
signaling, both WT and AS slices responded similarly (Figure 2A),
with phosphorylated forms of Erk (p-Erk1/2) being significantly
elevated within 15 min following the application of BDNF
(25 ng ml21), and remaining elevated for at least 60 min (AS

Results
CN2097, a PSD-95 PDZ Peptidomimetic Ligand, Promotes
LTP in Angelman Mice
PSD-95 has been shown to regulate synaptic strength and is
proposed play a key role in LTP [25,26,43–45]. Previously, we
developed a bridged cyclic peptide (CN2097; Figure S1A), that
binds with high affinity to the PDZ1-PDZ2 domains of PSD-95
[33,34], and incorporates a polyarginine peptide to enable uptake
by neurons (Figure S1B). To examine the effects of CN2097 on
LTP, field excitatory postsynaptic potentials (fEPSPs) were elicited
PLOS Biology | www.plosbiology.org
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and WT; n = 4). These results suggest that BDNF-induced Erk
signaling is normal in AS mice, and infer that TrkB receptor
activation is intact. Confirming that TrkB activation is unaffected,
we saw no significant difference in the level of TrkB expression or
TrkB phosphorylation in lysates prepared from freshly isolated
WT and AS hippocampal tissue (Figure 3B), or hippocampal slices
(p.0.05; Figure 4A, input blot). In contrast to undetectable
changes in BDNF-induced Erk activation in the AS-mouse, severe
signaling defects were observed in both the PI3K and PLCc1
downstream signaling cascades (Figure 2A). As a measure of
BDNF-induced PI3K activity, we examined the phosphorylation
state of its downstream effector, the serine/threonine kinase Akt
[49]. The level of p-Akt (Ser473) in AS mice, at 30 min postBDNF, was 18%64.9% of WT (p,0.001, n = 4; Figure 2A, top
panel, and quantitative analysis, lower panel). Similarly, peak
BDNF-induced phosphorylation of CaMKIIa (Thr286) and
CREB (Ser133) was lower, reaching levels of only 14%63.5%
and 41%65.5%, respectively, compared to WT (p,0.001, n = 4;
Figure 2A, top panel, and quantitative analysis, lower panel). As
reported previously [8], we found that the level of basal pCaMKIIa (Thr286) in AS mice was greater than WT
(201%622% at 09, # in Figures 2A and S2A), while total
CaMKII remained unchanged (Figure 2A). To confirm that the
reduced signaling was not a result of slice preparation or the
incubation period, we repeated the experiments using lysates made
from freshly dissected AS hippocampus, and found that basal pAkt and p-CREB were similarly diminished (p,0.01, n = 3;
Figure 2B). It is also worth noting that basal levels of Arc in AS
mice were approximately 2-fold higher than in WT (224%627%,
p,0.01; Figure 2B).
As CN2097 facilitated LTP in AS and WT mice, we examined
whether CN2097 altered BDNF-TrkB signaling. In both WT and
AS brain slices CN2097 increased BDNF-induced downstream
signaling of PLCc1 (p-CaMKIIa and p-CREB) and PI3K (p-Akt)
pathways, but did not alter Erk phosphorylation (Figure 2A, top
panel, and quantitative analysis, lower panel). Specifically, in WT
slices, CN2097 elicited increases in BDNF-induced p-CaMKII of
55%613.5%, (309, p,0.01, n = 4) and p-Akt of 93%632%, (309,
p,0.05, n = 4), whereas the control compound CN5135 had no
effect (p.0.1, n = 4; Figures 2A and S2A), demonstrating the
specificity of CN2097. Significantly, in AS-slices, CN2097
increased p-CaMKII (86%611% at 309, p = 0.21, n = 4) and pAkt (89%622% at 309, p = 0.35, n = 4) to levels comparable to WT
slices (Figure 2A). In the absence of BDNF stimulation CN2097
had no effect in both WT and AS brain slices (Figures 2 and S2A).
These results suggest that CN2097 acts downstream of TrkB to
facilitate activation of the PI3K and PLCc pathways. However, in
brain slices we cannot rule out that CN2097 enhances synaptic
activity to indirectly potentiate TrkB signaling [55]. To study TrkB
signaling in isolation of synaptic influences, we heterologously
expressed TrkB in SH-SY5Y neuroblastoma cells (SH-SY5YTrkB). Although this cell line does not express endogenous TrkB, it
expresses PSD-95, Ube3A, and Arc, making it a useful in vitro
system to explore the role of these proteins in BDNF signaling.
Upon BDNF stimulation of SH-SY5Y-TrkB cells, CN2097
enhanced phosphorylation of Akt (Ser473 and Thr308),
GSK3a/b, and the mTORC1 downstream targets 4E-BP1 and
ribosomal protein p70S6K (Figure 2C; n = 5), demonstrating that
CN2097 directly targets downstream TrkB signaling.
The observed deficits in BDNF signaling in Ube3A knockout
mice could also reflect indirect or developmental abnormalities.
To directly assess whether Ube3A influences TrkB signaling, we
used RNAi to acutely deplete Ube3A in primary cultures of mouse
cerebellar granule neurons (CGN), where BDNF-TrkB signaling is

Figure 1. Defective BDNF-mediated synaptic plasticity in AS
mice is mitigated by CN2097. Field EPSP slopes plotted as a
percentage of pre-tetanus baseline in the CA1 region of the
hippocampus. (A) LTP in WT mice. A single HFS train (16 HFS; 1-s
train at 100 Hz) was insufficient to induce LTP (open circles), whereas 261-s trains at 100 Hz separated by 15-s resulted in LTP (blue diamonds;
26 HFS). Following application of 2 mM CN2097 for 30 min, a 16 HFS
stimulus now produced significant LTP (red dots, CN2097) comparable
to the 26HFS protocol (blue diamonds). A single HFS in the presence of
the negative control CN5135 had no effect on LTP (black dots, CN5135).
Red bar, time of drug application. (B) LTP in AS mice. Three HFS trains
10 s apart (36 HFS) had no significant effect on fEPSP slopes (open
circles, no drug). Following application of 2 mM CN2097 for 30 min, the
36HFS stimulation protocol resulted in LTP (red dots, CN2097). No such
effect was observed when the slices were incubated with the control
peptide CN5135 (black dots). For comparison, WT LTP induced using
the 26 HFS is shown (blue line, same data as in [A]; fitted using IGOR
Pro program). Red bar, time of drug application. (C) CN2097 (2 mM, red
bar) had no significant effect on baseline synaptic transmission either in
WT (top) or AS mice (bottom).
doi:10.1371/journal.pbio.1001478.g001
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Figure 2. Defective BDNF signaling in AS mice and rescue with CN2097. (A) CN2097 enhances defective BDNF induced CaMKII/CREB and Akt
phosphorylation in AS brain slices. Upper panel: Representative Western blots showing the relative abundance of phosphorylated protein (p-Erk1/2,
p-CaMKII, p-CREB, and p-Akt-S473) from lysates prepared from WT and AS brain slices. Slices were stimulated with BDNF (50 ng/ml) in the presence or
absence of CN2097 or the control compound CN5135 (2 mM; 30-min pretreatment). Slices were evaluated at designated times (‘, min) following BDNF
treatment. The level of basal p-CamKIIa (phospho-Thr286) is enhanced in AS untreated slices compared to WT (09, lanes indicated with a #). Total
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Erk1/2, Akt1/2, and CaMKII loading controls are shown. Lower panel: Quantitative analyses of p-Akt, p-CaMKII, and p-Erk after 30 min BDNF treatment,
normalized to individual loading controls. Statistical significance was calculated using a two-tailed Student’s t test. Data are mean 6 SEM from at least
three independent experiments. *p,0.05. (B) Freshly dissected AS mouse hippocampus show lower endogenous p-Akt and p-CREB expression and
more Arc expression versus WT mouse. Representative Western blots showing the relative abundance of phosphorylated protein (p-CREB and p-AktS473) in lysates. Erk1/2, Akt1/2, and Arc are shown. Optical densities normalized to WT (left lane) are indicated below selected rows. (C) CN2097
enhances BDNF-induced PI3K/Akt/mTORC1, but not Erk signaling in SH-SY5Y cells. SH-SY5Y cells transfected with control empty vector (Vector) or
TrkB cDNA (48 h) were treated with BDNF (25 ng/ml) in the presence or absence of CN2097 (2 mM, 20-min pretreatment) for the indicated time
points. Phosphorylation of Akt, GSK, S6 (p70S6K), 4E-BP1, and TrkB were detected using indicated antibodies. Total, TrkA, and TrkB are shown to
confirm equal sample loading and equivalent levels of TrkB-cDNA expression respectively. (D) Western blot analysis showing knockdown of Ube3A in
WT CGNs inhibits BDNF signaling. CGNs (CGN; age p5) transfected with scrambled control (scRNAi, 200 nM, 24 h) or Ube3A siRNA oligonucleotides
(200 nM, 24 h) were serum starved and treated with BDNF (25 ng/ml) in the presence or absence of CN2097 (2 mM, 20-min pretreatment) for
indicated time points. Western blots were probed for phosphorylation of Erk, CaMKIIb and Akt; total CaMKII, Akt, and b-actin were detected as
loading controls.
doi:10.1371/journal.pbio.1001478.g002

for PSD-95 in neurotrophin signaling. In contrast, BDNF-induced
Erk signaling was normal, inferring that PSD-95 knockdown did
not affect TrkB receptor activation. In support of this, PSD-95
knockdown did not alter the levels of TrkB expression or activation
in CGNs or SH-SY5Y cells (Figure S3C). PSD-95 knockdown in
SH-SY5Y-TrkB cells also blocked Akt and CaMKII, but not Erk
activation (Figure S3C). The specificity of the PSD-95 RNAi was
demonstrated by coexpressing RNAi resistant PSD-95 along with
a pRS plasmid containing the shRNA to PSD-95 (sh95A) in SHSY5Y-TrkB cells, which restored Akt signaling (Figure S3F).
Further supporting that the signaling defects are a result of
reduced PSD-95 expression, a second previously characterized
PSD-95 shRNA construct (sh95B) [44], similarly decreased Akt
and S6 activation (Figure S3F). Importantly, the knockdown of
PSD-95 abrogated CN2097 rescue of p-Akt and p-CaMKII
signaling (p,0.001; Figures 3C and S3C), lending support to the
hypothesis that the mechanism by which CN2097 rescues
signaling is through its interaction with PSD-95.
If PSD-95 acts as an intermediate in TrkB activation of PLCc1
and PI3K signaling, then increasing PSD-95 levels would be
predicted to enhance BDNF signaling. The exogenous expression
of PSD-95 in neurons could generate ambiguous results, as PSD95 promotes synaptic maturation [26], which could indirectly
potentiate TrkB signaling [55]. To examine whether increased
levels of PSD-95 enhance TrkB signaling, we again utilized the
simplified SH-SY5Y cell line system, where TrkB and PSD-95
were exogenously expressed. We found that overexpressing PSD95 in SH-SY5Y-TrkB cells increased BDNF-induced phosphorylation of Akt (S473, T308), GSK3b, CaMKIIa (T286), and the
mTORC1 downstream target p70S6K, while leaving p-Erk and pTrkB unaffected (Figures 3D and S3D for quantitative analysis).
Thus, increasing the levels of PSD-95 mimic the effect of CN2097
on BDNF signaling, leading to the hypothesis that even though
PSD-95 expression in AS mice is similar to WT, PSD-95 function
is compromised. All indications from this study are that CN2097
increases the amount of PSD-95 available to bind to TrkB, which
in turn facilitates signaling. Extending this rational, increasing the
levels of PSD-95 would be predicted to overcome the effects of
Ube3A knockdown. Testing this hypothesis, we found that
overexpression of PSD-95 in SH-SY5Y-TrkB cells, in which
Ube3A was knocked down, partially restored BDNF-induced Akt
(S473 and T308) and CaMKII phosphorylation (Figures 3E and
S3E for quantitative analysis). Co-transfection with other related
MAGUKS (SAP97, SAP102, and Chapsyn110) did not facilitate
TrkB-induced p-Akt or p-S6 signaling (Figure S3G), which is
consistent with the higher PDZ binding affinity of CN2097 for
PSD-95 and not these MAGUKs [33]. We also would anticipate
that if CN2097 is specific for PSD-95, it should not affect signaling
pathways that do not involve PSD-95. In agreement, neither
CN2097 nor PSD-95 knockdown had any effect on altering

known to play a critical role in CGN development and survival
[56–58]. Recapitulating the AS hippocampal slice results, acute
knockdown of Ube3A in WT CGNs (to 18%610% of scrambled
RNAi protein levels), had no effect on p-Erk signaling but severely
reduced BDNF-mediated p-CaMKIIb the isoform of CaMKII
that is highly expressed in mouse CG neurons [59,60], and p-Akt
(S473) signaling (p,0.005; Figure 2D). Similar to the responses
documented in the AS slice studies shown above, p-Akt and pCaMKII levels were restored to WT levels with CN2097
pretreatment (Figure 2D; p.0.1). In addition, knockdown of
Ube3A in SH-SY5Y-TrkB cells (to 10%63.0% of untransfected
protein levels), produced identical deficits in BDNF signaling
(Figure S2B, upper panel, and quantitative analysis, lower right
panel), and enhanced expression of Arc, a previously identified
Ube3A substrate (Figure S2B, middle right panel) [10]. The
specificity of the RNAi was demonstrated by coexpression with
recombinant Ube3A, which rescued signaling (Figure S2C, upper
panel).
Defective recruitment of signaling intermediates to TrkB could
explain the deficits in Akt and CaMKII signaling observed in AS
mice [49]. Using coimmunoprecipitation (co-IP) studies, we
examined the association of Grb2-associated binder 1 (Gab1), a
major adaptor protein required for BDNF activation of the PI3KAkt cascade [48,49], and PSD-95, which has been shown to
coimmunoprecipitate with TrkB [50,61]. In contrast to WT brain
slices where BDNF increased PLCc, Gab1 (Figure 3A, upper
panel) and PSD-95 (Figure 3A, lower panel, and Figure 4A, upper
panel) recruitment to TrkB, these interactions were diminished in
AS slices (PLCc, 28%64%; Gab1, 23%65.5%; and PSD-95,
15%64%; p,0.001 compared to WT; Figures 3A and 4A).
CN2097 improved the association of PLCc (71%64%), Gab1
(62%614%), and PSD-95 (53%69%), with TrkB in AS slices, and
enhanced these interactions in WT slices (,50%, p,0.001;
Figures 3A and 4A). Consistent with these results, co-IP studies
performed on freshly dissected hippocampal and cerebellar AS
tissue also showed reduced association of PSD-95 and Gab1 with
TrkB (p,0.01; Figure 3B). The similar deficits in both the
hippocampus and cerebellum are consistent with a lack of Ube3A
expression in these brain regions [62,63]. Overall, the observed
deficits in TrkB signaling in AS mice are consistent with the
inability of TrkB to associate with specific signaling adaptors
(Figure 4D).

PSD-95 Is Required for BDNF Signaling
We next tested whether the presence of PSD-95 is required for
BDNF-induced PLCc1 and PI3K signaling. RNAi knockdown of
PSD-95 using a synthetic siRNA duplex (sh95A) was highly
effective in primary CGN cultures (18.7%68.9% compared to
WT), and significantly reduced BDNF-induced phosphorylation of
Akt and CaMKII (p,0.01; Figure 3C), identifying a unique role
PLOS Biology | www.plosbiology.org
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Figure 3. The role of PSD-95 in TrkB signaling. (A) Co-IP analysis showing the association of TrkB with PLCc, Gab1, and PSD-95 is reduced in AS
brain slices, and CN2097 restored these interactions. Representative Western blots for immunoprecipitation with an antibody to TrkB or a beads alone
control (Beads), and immunoblotting with antibodies to TrkB, PLCc, Gab1 (left upper panel) and TrkB and PSD-95 (left lower panel). Brain slices from
both WT and AS littermates were pretreated with CN2097 (2 mM; for 30 min) followed by BDNF treatment (50 ng/ml). Input lanes (see Figure S3A)
show the expression level of TrkB, PLCc, and b-actin. Numbers below selected rows represent normalized optical density (OD) values. (B) Co-IP
analysis showing the association of TrkB with Gab1 and PSD-95 is reduced in freshly dissected AS mouse hippocampus (upper) and cerebellum
(lower). Representative Western blots for immunoprecipitation with antibodies to TrkB or IgG control, and immunoblotting with antibodies to TrkB,
p-TrkB, Gab1, and PSD-95. Input lanes are shown in Figure S3B. Numbers below selected rows represent normalized OD values. (C) PSD-95 RNAi
knockdown in CGNs inhibits BDNF signaling. Western blot analysis of PSD-95 expression and phosphorylation of Erk, CaMKIIb, and Akt as a loading
control. Erk1/2, generated from an identically loaded sister gel, is also shown. Primary mouse CGNs (CGNs, p5) transfected with scrambled control
(scRNAi, 200 nM, 24 h) or PSD-95 siRNA oligonucleotides (sh95A; 200 nM, 24 h) were serum starved and treated with BDNF (25 ng/ml) in the
presence or absence of CN2097 (2 mM, 20-min pretreatment). (D) Western blot analysis showing that overexpression of PSD-95 enhances BDNFinduced p-Akt and p-CaMKII, but not p-Erk or p-TrkB in SH-SY5Y-TrkB transfected cells. SH-SY5Y cells were transfected with TrkB+control empty
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vector or TrkB+PSD-95 cDNA for 48 h. Cells were treated with BDNF (25 ng/ml). Results show that increased levels of PSD-95 enhance BDNF-signaling
of p-Akt (S473 and T308), p-CaMKII, pGSK3a/b, and p-S6. Akt1/2 and p-Akt (S473) were generated from an identically loaded sister gel. Akt1/2 and
Erk1/2 demonstrate equal sample loading. Quantitation showing p-CaMKII and p-Akt but not p-Erk were significantly enhanced is shown in Figure
S3D. (E) Western blot analysis showing that overexpression of PSD-95 restores BDNF signaling in Ube3A RNAi knockdown SH-SY5Y cells. SH-SY5Y cells
transfected (48 h) with vector alone, TrkB+scramble shRNA (sc-RNAi), TrkB+Ube3A shRNA, TrkB+Ube3A shRNA+PSD-95, were treated with BDNF
(25 ng/ml) for indicated time points. Western blots were probed with antibodies to Ube3A, p-Akt (S473 and T308), p-CaMKII, and the loading control,
b-actin. p-Akt and p-CaMKII were generated from an identically loaded sister gel. Quantitation showing that overexpression of PSD-95 enhanced both
p-Akt (p,0.01) and p-CaMKII (p,0.01) is shown in Figure S3E.
doi:10.1371/journal.pbio.1001478.g003

insulin-like growth factor-1 (IGF) (Figure S3H) or epidermal
growth factor induced signaling (unpublished data). Overall, these
results show that PSD-95 plays a key role in BDNF-induced
PLCc1 and PI3K signaling, and suggest that in Ube3A-deficient
neurons the association of PSD-95 with TrkB is decreased,
resulting in defective signaling.

WT, resulting in increased expression of Arc. These AS cultures
exhibited reduced BDNF-induced Akt signaling (comparing scRNAi transfected WT and AS, p,0.01; Figure 4C), consistent
with the Arc overexpression studies performed in SH-SY5Y-TrkB
cells (Figure 4B). Arc-RNAi reduced Arc expression, and in AS
neurons restored BDNF-induced Akt phosphorylation to WT
control levels (p.0.1). We also observed that knockdown of Arc in
WT neurons decreased BDNF-induced Akt signaling (Figure 4C;
p,0.01), suggesting that basal levels of Arc are needed for TrkB
signaling. This observation is not unexpected as the expression of
Arc appears to be finely tuned to regulate LTP [11,12,66],
endocytosis [16], and LTD [12,17].

Elevated Levels of Arc Attenuate BDNF-TrkB Signaling
Loss of Ube3A expression in AS mice result in increased levels
of Arc (Figures 2B and 4A, lower panel), which has been shown to
deleteriously affect synaptic plasticity [10,16]. Arc has been
reported to bind the SH3-GK domain of PSD-95 [64], and
proteomic studies show that Arc is one of the proteins to co-purify
with PSD-95 [19], raising the possibility that Arc’s association with
PSD-95 influences BDNF signaling. Co-IP studies performed from
hippocampal slices are consistent with this hypothesis, showing
that higher amounts of Arc co-IP with PSD-95 in AS compared to
WT slices (Figures 4A, upper blot, and S4A, upper panel for
quantification). Conversely, higher amounts of PSD-95 co-IP with
Arc in AS compared to WT slices (Figures 4A, lower panel, and
S4A, lower panel showing co-IP performed with normalized Arc
levels). Interestingly, Arc appears to associate with PSD-95
independently of BDNF stimulation (Figure 4A), which was also
observed in SH-SY5Y-TrkB cells co-expressing Arc-myc (Figure
S4B, upper and quantitation in middle panel). Treatment of the
brain slices with CN2097 reduced the Arc-PSD-95 interaction,
which was coincident with increased association of TrkB receptors
with PSD-95 (Figure 4A).
To directly test the hypothesis that Arc expression can interfere
with BDNF signaling, we expressed Arc in SH-SY5Y-TrkB cells
and examined TrkB signaling. Arc overexpression decreased the
levels of BDNF-induced p-Akt, p-CaMKII, p-4EBP1, p-S6
(Figures 4B and S4B, lower panel quantitation), but not p-Erk or
p-TrkB, identical to knockdown of PSD-95 (Figure 3C). Significantly, CN2097 restored the defective CaMKII, Akt, 4EBP1, and
S6 signaling resulting from Arc overexpression to control levels
(Figures 4B and S4B, lower panel quantitation), and disrupted the
interaction between Arc and PSD-95, with a concomitant increase
in BDNF-induced TrkB-PSD-95 association (Figure S4B, middle
panel). In a different approach to increase Arc levels we expressed
a dominant negative Ube3A (E6AP C833A) [65] in the SH-SY5YTrkB cells. We also observed significantly reduced BDNF-induced
p-Akt signaling when compared to SH-SY5Y-TrkB control cells
(Figure S4C), which was rescued with an Arc-shRNA (Figure S4C)
[10].
If Arc is a critical inhibitor of PSD-95-TrkB interaction and
downstream signaling in AS mice, then decreasing Arc expression
in AS neurons would be predicted to rescue TrkB downstream
signaling. Using a previously described Arc siRNA [10], we
knocked down Arc in primary cultures of CGNs prepared from
the cerebellum of individual postnatal (day 5) WT and AS mice.
Ube3A expression is extremely low in the cerebellum of AS mice
(Figure S3B), and as shown in Figure 4C, AS granule neuron
cultures had greatly reduced expression of Ube3A compared to
PLOS Biology | www.plosbiology.org

AS Mice Exhibit Deficits in PSD-95 and Synaptophysin
Synaptic Localization
TrkB signaling has been reported to be required for synaptic
localization of PSD-95 [50] and excitatory synapse formation [67].
This finding, together with the observation that AS mice exhibit
abnormal synapse formation in the CA1 region of the hippocampus [62], suggests that the synaptic localization of PSD-95 may be
reduced in AS neurons. To investigate this we performed a
quantitative analysis of synaptic puncta density in the hippocampal
CA1, CA3, and dentate gyrus (DG) subregions, using antibodies to
synaptophysin (SYN) and PSD-95 to visualize presynaptic and
postsynaptic specializations, respectively.
To first examine for differences between WT and AS mice we
used Image J software to compare the relative numbers and
intensity of staining of discrete PSD-95 and SYN immunolabeled
puncta in the CA1, CA3, and DG subregions (Figure S5).
Importantly, in the CA1 stratum radiatum (CA1-SR) region, AS
mice exhibited a significant reduction in the number of PSD-95positive puncta (0.71060.026 puncta/mm2, p,0.05, 16.2%)
compared to control mice (0.84760.055 PSD-95 puncta/mm2;
Figure S5A), with no significant reduction in CA3 or DG regions
(Figure S5E and S5I). Examination of presynaptic puncta revealed
a significant reduction in the number of SYN puncta in both the
CA1 (Figure S5B) and CA3 subregions of the AS mouse (Figure
S5F), with the greatest reduction occurring in CA1-SR region
(28.0%) (Figure S5B). However, no difference in SYN puncta was
detected in DG (Figure S5J) between AS and WT mice. In
addition to a decline in SYN-puncta in the AS mouse, the total
puncta intensity of CA1 SYN-IR was significantly reduced in
CA1-SR (Figures 5E, insert, and S5D) compared with WT
(Figures 5B, insert, and S5D). A significant reduction of SYNstaining intensity was also shown in the neuropil of CA3 (Figure
S5F), but not in the DG (Figure S5J). Overall, these data indicate
that the CA1 region in the AS mouse has a significant reduction in
both PSD-95 and SYN puncta density and intensity. Independent
conformation of SYN-decline in the hippocampus of the AS
mouse was demonstrated by Western blot (Figure 5J).
We next addressed whether the number of PSD-95 contacts
with SYN-IR puncta (synaptic density) was affected. Although the
use of image analysis software was able to show significant relative
differences between AS and WT mice in the distinct regions of the
7
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Figure 4. Arc interacts with PSD-95 to inhibit TrkB signaling, while CN2097 disrupts the Arc/PSD-95 association to restore
signaling. (A) Upper panel: Co-IP with an antibody to PSD-95, and immunoblotting for Arc, show increased of Arc/PSD-95 association in AS brain
slices compared to WT (p,0.05). AS slices pretreated with CN2097 significantly reduced Arc association with PSD-95 (p.0.1) to levels approaching
WT. Numbers below selected rows represent normalized optical density (OD) values. See quantitation in Figure S4A. BDNF-induced association of
PSD-95 with TrkB was diminished in AS compared to WT and was significantly increased in the presence of CN2097 (109, p,0.05). Sample input was
normalized to equal levels of TrkB as shown. Lower panel: Co-IP with an antibody to Arc and immunoblotting for PSD-95, show that Arc association
with PSD-95 is elevated in the AS brain slices compared to WT, and that this association is not influenced by BDNF. However, pretreatment with
CN2097 reduced PSD-95 association with Arc to levels approaching WT. The expression levels of PSD-95, Akt, and Arc were detected from each lysate
as input control. Upper and lower panel: Coronal brain slices (hippocampus and cortex) after BDNF (50 ng/ml, 10 min) with or without CN2097 (2 mM,
30-min pretreatment). (B) Arc inhibits BDNF-induced signaling. Western blot showing that expression of c-myc-tagged Arc inhibits BDNF-induced pCaMKII, p-Akt, p-4EBP1, p-S6 (p70S6K), but not p-Erk or p-TrkB signaling in SH-SY5Y, and CN2097 rescues. SH-SY5Y cells were transfected with empty
vector control+TrkB or TrkB+Arc-myc cDNA for 48 h were treated with BDNF (25 ng/ml) with or without CN2097 (2 mM, 20-min pretreatment). The
phosphorylation levels of Akt, CaMKII, 4E-BP1, S6, Erk, and TrkB and their loading controls were detected. CaMKII, p-CaMKII, and TrkB blots were
generated from an identically loaded sister gel. Quantitation showing that Arc expression results in significantly lower p-Akt and p-CaMKII (p,0.05),
which is restored to control levels by CN2097 (p-Akt, p.0.1; p-CaMKII, p.0.1) is shown in Figure S4B (lower panel). (C) Knockdown of Arc rescues
BDNF signaling in AS CGN cultures. Representative Western blots probed for phosphorylation of Akt and TrkB; total Akt, Arc, and Ube3A (generated
from an identically loaded sister gel) were detected. in lysates prepared from primary cultures of CGNs, derived from WT and AS mice at postnatal day
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6. CGNs transfected with scrambled control (scRNAi, 200 nM, 24 h) or Arc siRNA oligonucleotides (100 nM, 24 h), at p5, were serum starved and
treated with BDNF (25 ng/ml; 109). (D) Possible role of PSD-95 in TrkB-signaling pathways. In response to TrkB stimulation, PSD-95 is recruited to TrkB,
resulting in enhanced PI3K-Akt-mTOR and PLCc1 signaling, whereas ERK activation is independent of PSD-95. The activation of the PI3K-Akt and the
PLCc1/protein kinase C (PKC) pathways may feedback and enhance the synaptic delivery of PSD-95 and TrkB signaling [50,72]. In AS, loss of Ube3A
expression results in increased levels of Arc, which associate with PSD-95 to inhibit PSD-95 recruitment to TrkB. CN2097 binds to PSD-95 to disrupt
Arc association and rescues signaling.
doi:10.1371/journal.pbio.1001478.g004

and a decrease in the intensity of PSD-95 puncta colocalized with
SYN (Figure 5I and 5K). These results are compatible with the
reported abnormalities in spine morphology, number, and length
in CA1 pyramidal neurons of Ube3a maternal-deficient mice [62],
and are consistent with the impaired LTP in this region
(Figure 1B), and compromised cell signaling mediated by
BDNF/TrkB in CA1 pyramidal cells.
We have identified PSD-95 as a novel TrkB-associated protein,
critical for full activation of downstream PI3K-Akt and PLCc
signaling. We found that BDNF-induced association of PSD-95
with TrkB is impaired in Ube3A m2\p+ mice, resulting in reduced
activation of signaling molecules downstream of TrkB, including
Akt-mTORC1 and PLCc-CaMKII, whereas the Erk pathway
appeared intact. The in vivo defects in BDNF signaling observed
in AS mice were recapitulated in vitro by depletion of Ube3A or
increasing the expression of Arc, while elevating the expression of
PSD-95 restored defective signaling. Moreover, a bridged cyclic
peptide (CN2097) shown by nuclear magnetic resonance (NMR)
studies to uniquely bind the PDZ1 domain of PSD-95 with high
affinity [33,34] enhanced BDNF-induced TrkB-PSD-95 complex
formation, to improve signaling in AS brain slices. Depletion
studies show that PSD-95 is essential for the effectiveness of
CN2097 restoration of signaling in Ube3 deficient neurons. Rescue
of BDNF signaling by CN2097 was shown to strongly correlate
with the ability of CN2097 to decrease PSD-95 association with
Arc. Overall, these studies demonstrate PSD-95 enhances TrkBinduced PLCc and PI3K signaling pathways (Figure 4D), which
could further facilitate PSD-95 trafficking to synapses [50] and
modulate NMDA receptor-dependent synaptic plasticity [69,74].
In addition to postsynaptic signaling deficits in the AS mouse,
we also observed deficiencies in the presynaptic terminals, where
immunostaining for the synaptic vesicle protein SYN was shown to
be significantly less in CA1-SR in the AS mouse (Figure 5E, inset),
as compared with a WT littermate (Figure 5B, inset). In agreement
with the reduction of the average intensity of SYN puncta (,53%;
Figure S5D), the expression level of SYN in the hippocampus of
Ube3A m2\p+ mice, by Western blotting, was greatly reduced
(,30%; Figure 5J), as reported previously [75]. In addition, there
was a significant reduction in the number of SYN puncta in this
region of the AS mouse (Figure 5H). It is possible that loss of
Ube3A, which has been shown to also localize to the presynaptic
compartment [62], leads to an impairment in presynaptic
function. In support of this, Philpot and colleagues found a
decrease in the number of synaptic vesicles at both excitatory and
inhibitory synapses of Ube3am2/p+ mice, resulting in a severe
deficit in inhibitory drive to neocortical pyramidal neurons [76].
Alternatively, the reduction in the number of SYN puncta in AS
mice could be the indirect result of defective transsynaptic BDNF
signaling [53,54]. BDNF and TrkB knockout mice also show a
reduction in SYN levels in synaptosomes, leading to a reduction in
docked synaptic vesicles and synaptic fatigue [46,73,77].
Prolonged BDNF treatment reversed the synaptic fatigue observed
in BDNF knockout mice, suggesting a role for BDNF in the
mobilization and/or docking of synaptic vesicles [35,46].
Mechanistically, the specific function of PSD-95 in BDNFmediated signaling remains to be elucidated. Increasing evidence

hippocampus, these data were limited by the minimal thresholding
capabilities of the software, whereby faintly stained puncta,
particularly in the AS mouse, were not recorded. In order to get
an accurate assessment of the synaptic density in CA1, manual
counting the number of PSD-95 (Figure 5A and 5D), SYN
(Figure 5B and 5E), and their synaptic contacts (Figure 5C and 5F)
was preformed (See Methods for description of manual counting).
In agreement with previous reports [67], the distribution of PSD95-IR puncta averaged 1.29 puncta/mm260.03, and the synaptic
density averaged 0.9560.03 in the WT mouse (Figure 5G and 5I).
In the AS-CA1 region, we found that there was a significant
reduction in both the number of PSD-95-IR puncta (Figure 5G;
1.15 puncta/mm260.02: p,0.01, two-tailed t test, with normality
tested and confirmed using the method of Kolmogorov and
Smirnov), as well as the number of synaptic contacts between
PSD-95 and SYN (Figure 5I; 0.82 contacts/mm260.02, p,0.01),
which translates to a 10.9% reduction of PSD-95-IR puncta and a
13.7% decline in synaptic density in the AS-mouse within the
neuropil region of CA1. These data confirm that in the AS CA1
region there is a significant reduction in the number of synapses.
Confirming that the PSD-95-IR staining was in agreement with
previous reports in the WT-mouse [67], we next sought to
determine if there is a shift in the distribution of staining intensity
of individual PSD-95-puncta making contact with SYN in the ASmouse. Mean intensity for each synaptic PSD-95 puncta was
measured by placing a 34-pixel circle over the punctum using
ImageJ (see Methods). Results showed that the mean intensity of
puncta in AS CA1 was lower than WT (Figure 5K), and plotting
the distribution of all measured puncta as a function of mean
intensity showed that there is a shift to the left in the AS mouse,
indicating that a significant number of synaptic PSD-95-IR puncta
in the AS mouse are less intensely stained than in WT. Also,
despite this shift to less-intensely stained synaptic puncta in the AS
mouse, there was no difference noted between AS and WT CA1SR in the average intensity distribution of all identified PSD-95
stained puncta (Figure S5C), indicating that synaptic PSD-95
puncta are preferentially compromised. A similar loss in synaptic
PSD-95 staining intensity was observed in the DG region
(Figure 5M) but not in the CA3 (Figure 5L). These results are
consistent with deficits in TrkB signaling [50].

Discussion
Numerous studies show that BDNF plays a critical role in
synaptic plasticity and memory [68,69]. Significantly, the deficits
in synaptic plasticity observed in AS mice are similar to those in
BDNF or TrkB mutant mice [40–42]. TrkB-PLCc signaling on
both sides of the synapse has been reported to be required for LTP
induction [70], and synaptic activity is believed to trigger the
secretion of BDNF either pre- [71] or post-synaptically [47], to
activate postsynaptic TrkB-PI3K signaling and increase PSD-95
transport to synapses [50,72]. Suppression of TrkB signaling leads
to a reduction in the number and intensity of PSD-95 puncta
along dendrites [72] and TrkB knock-out mice show decreased
numbers of hippocampal Schaffer collateral excitatory synapses
[67,73]. Our data show that in the hippocampal CA1 region of AS
mice there is a significant reduction in the number of synapses,
PLOS Biology | www.plosbiology.org

9

February 2013 | Volume 11 | Issue 2 | e1001478

TrkB-PSD-95 signaling in Angelman Syndrome

Figure 5. Decreased synaptic density in the CA1 hippocampal area. PSD-95 (green, A and D) and SYN (red, B and E) antibodies were used to
stain synapses (merged, C and F) in stratum radiatum (SR) of the hippocampal area CA1. Here differences in PSD-95 and SYN staining were observed
between WT and AS mice. In the case of SYN, there was a noticeable decline in staining intensity in the AS mouse (see unthresholded image in the
inset of [E] compared to the unthresholded image taken from the WT mouse (see inset of [B]). Quantitative data for PSD-95 (G) and SYN (H) show a
significantly reduced number of PSD-95 and SYN stained puncta in the AS mouse. Importantly, the total number of PSD-95/SYN contacts (synaptic
density) was also decreased in the AS mouse (I). Western blot analysis of WT and AS hippocampus shows no visual differences in PSD-95 levels
between WT and AS mice (J); however, there was roughly a 35% lower level of expression of SYN in AS than in WT. Measurement of synaptic PSD-95
puncta intensities are shown in CA1 (K), CA3 (L), and DG (M). In both CA1 (K) and to a lesser extent in the DG region (M), there was a shift to the left
with respect to the number of puncta that were less intensely stained in the AS mouse as compared with WT. In contrast no differences were noted in
CA3 (L). Immunostained sections were imaged on a confocal microscope using 1006 objective and a 46 zoom. Scale bar = 7.5 mm. (*p,0.05).
doi:10.1371/journal.pbio.1001478.g005
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stimulation of the Schaffer Collaterals with 0.3-ms square wave
pulses with a concentric bipolar electrode. Stimulation intensity
was adjusted to record stable (,5% drift) fEPSPs at 50% of
maximum amplitudes (.2 mV minimum). fEPSPs were recorded
(AxoClamp2B amplifier, Axon instruments), Bessel filtered at 1 Hz
and 1 kHz (Dagan, EX1 Differential Amplifier), digitized at
10 kHz (NI BNC2010A), and stored for analysis (Igor pro,
Neuromatic and nClamp, www.neuromatic.thinkrandom.com).
HFS trains consisted of one, two, or three 1-s 100-Hz, 0.2-ms pulse
duration, over 30 s. Effects were presented as average 6 SEM.
Significance was determined using paired t tests.

indicates that Trk activation of differential signaling pathways is
tied to their internalization and trafficking to endosomes [78,79].
Lipid rafts also appear to be essential for Trk-activation of the
PLCc pathway [80]. Interestingly, in Fyn-deficient mice TrkB
translocation to lipid rafts is prevented and mice exhibit
compromised BDNF-induced PLCc, PI3K-Akt, but not Erk
signaling [80], identical to our findings in AS mice. PSD-95,
which associates with lipid rafts by palmitoylation [81], and has
been shown to bind Fyn [82], may be required for the intracellular
sorting or retention of TrkB to lipid rafts [83].
Our data are consistent with the hypothesis that, in AS mice,
the increased levels of Arc and its association with PSD-95
interfere with BDNF/TrkB-dependent recruitment of PSD-95
(Figures 3A and 4A). However, it still remains to be determined if
Arc directly binds to PSD-95 or if linking proteins are required for
its association. One possibility is that Arc could bind indirectly to
PSD-95 via dynamin or endophilin to regulate TrkB endocytic
trafficking and signaling from early endosomes. Trk signaling is
dependent on internalization via a dynamin-dependent process
and endophilins regulate BDNF-TrkA early endocytic trafficking
and signaling [84]. Arc directly binds and recruits endophilin and
dynamin to early/recycling endosomes [16], and recent studies
indicate that Arc plays a role in the postsynaptic trafficking of
amyloid precursor protein [85]. Furthermore, Arc and PSD-95 are
both critical for AMPAR trafficking [16,22,25,27,86], raising the
possibility that the association of Arc with PSD-95 may also
provide a mechanism to control AMPAR trafficking.
A number of recent studies aimed at restoring Ube3A activity in
the AS mouse demonstrate that it may be possible to improve
learning and memory in adult AS patients [87,88]. The discovery
that CN2097 can reinstate BDNF-signaling pathways in AS mice
to facilitate LTP suggests that the development of drugs targeting
PSD-95 may be beneficial in treating the behavioral deficits in AS.
Therapeutic strategies that enhance neurotrophin signaling may
be additionally advantageous as signaling through these receptors
appears to be compromised in other neurological diseases [89,90].

Animals
To obtain heterozygous AS mice missing the maternally
Ube3Am2/p+ gene, we crossed a heterozygous female mouse with
a WT male mouse. In all experiments we used male mice aged
between 2–4 mo. Control mice were age-matched, male, WT
littermates. Mice were raised on a 12-h light/dark cycle, with food
and water available ad libitum and were housed in groups of two
to three per cage. Electrophysiological recordings were obtained
from at least three mice for each condition. All animal procedures
were performed in compliance with the US Department of Health
and Human Services and the IACUC animal care guidelines at
Brown University.

CGN Purification
Methods for isolation and purification of murine and rat CGNs
were as previously described [91,92]. CGNs were purified from P5
mouse pups, resuspended in serum-free medium (SFM) and plated
at a density of 2.56106 cells/well, six-well plate) with poly-Lornithine (0.01%; Sigma) and mouse laminin (20 mg/ml; Invitrogen). SFM was composed of Eagle’s basal medium with Earle’s
salts (BME; Gibco) supplemented B27, bovine serum albumin
(10 mg/ml), all from Sigma, and glutamine (2 mM; Gibco),
glucose (0.5%) and penicillin/streptomycin (20 U/ml; Gibco).

Immunohistochemistry for Synapse Labeling and
Counting

Materials and Methods
Electrophysiological Recordings and Data Analysis

Brains were fixed by perfusion of the animals under deep anesthesia
(Ketamine, 75 mg/kg bw and Medetomidine, 0.5 mg/Kg bw, i.p.)
through the ascending aorta with 4% (w/v) paraformaldehyde in
0.1 M sodium phosphate buffer (PBS, pH 7.2); brains were removed
and immersed overnight at 4uC in the same solution. Brains were
then cryoprotected by soaking in 20% (w/v) sucrose in PBS (12 h,
4uC) and 30% (w/v) sucrose in PBS (8 h, 4uC) and frozen in
OCT by immersion in dry ice-cooled isopenthane. Brains were
sectioned into a series of 30-mm-thick frontal or coronal slices;
slices were post fixed, before the immunohistochemical staining,
with the fixative solution for 2 h at 37uC. Immunohistochemistry
was performed by the free-floating technique. After a 15 min
treatment with 0.3% (v/v) Triton X-100 (in PBS), slices were
immersed and gently shaken in a PBS-diluted (10%, v/v) horse
serum (HS), containing 5% (w/v) BSA for 4–5 h at room
temperature (‘‘blocking’’ step). The immunostaining step was
conducted by immersion and gentle shaking of the slices with the
primary antibodies, diluted with blocking medium (anti-PDS-95
rabbit polyclonal antibody, Cell Signal, 1:100 and anti-SYN
mouse monoclonal antibody, SY38, Abcam, 1:30), for 24–36 h at
4uC. Primary antibody specificity for PSD-95 and was confirmed
using Western blot, After washing (10 min in blocking medium,
three times), sections were incubated with secondary antibodies
diluted in blocking medium, as biotinylated anti-rabbit
antibody (Vector Laboratories,1:300) and anti-mouse Texas

2–4-mo-old male WT and AS mutant (Ube3Am2/p+) mice were
bred on a 129S7 background strain, supplied by Jackson laboratories
(stock number 00447) [6], were deeply anesthetized with isoflurane,
then decapitated. Brains were rapidly removed and placed in 4uC
dissecting solution (containing 60 mM NaCl, 3 mM KCl, 1.25 mM
NaH2PO4, 28 mM NaHCO3, 110 mM sucrose, 0.6 mM ascorbic
acid, 5 mM Dextrose, 7 mM MgCl2, and 0.5 mM CaCl2.H2O,
[pH 7.25–7.35]). Brains were then sectioned and glued to the stage of
a vibrating blade microtome (Vibratome) and coronal ‘‘brain slices’’
(450 mm) containing the dorsal hippocampus and adjoining cortex
were cut and incubated in a humidified interface chamber containing
oxygenated artificial cerebral spinal fluid (ACSF) (95% O2/5% CO2)
containing 119 mM NaCl, 2.5 mM KCl, 1 mM NaH2PO4, 26 mM
NaHCO3, 11 mM glucose, 1.3 mM MgSO4.7H2O, and 2.5 mM
CaCl2 with pH (7.25–7.35) at room temperature for .1–2 h prior to
use. For Western blot analyses, several brain slices were transferred to
room temperature 20-ml submersion chambers containing continually oxygenated ACSF. Test reagents were added directly to the
chamber.
For electrophysiological recordings, slices were transferred to a
1-ml submersion-type recording chamber perfused with 30uC,
oxygenated ACSF at 2 ml/min21. Borosilicate glass microelectrodes (resistance ,1 MV) were placed in CA1 stratum radiatum
for extracellular recordings. Synaptic responses were elicited by
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2000 (Life Technologies) in six-well plates. A pEGFP cDNA
plasmid was added to determine the efficiency of transfection
which was at least 30%–40% for each experiment.
For knockdown of Ube3A or PSD-95 primary CGNs, dense
cultures were grown for 3 d in vitro and then switched to DMEM
(no FCS) medium 1 h before transfection. 2 ml of Ube3A- or PSD95-specific RNAi duplexes (100 mM, diluted in siRNA dilution
buffer [Santa Cruz Biotechnology] and 3.0 ml of Lipofectamine
PLUS Reagent [Invitrogen]) were diluted in 90 ml of siRNA
dilution buffer. To this was added 2.8 ml of Lipofectamine LTX
and incubated for 30 min at room temperature. The complex was
added to the well containing 1 ml of DMEM for 2 h, with a final
siRNA concentration of 100 nM. 10% FCS medium was then
added back to the CGN and cultured for 24 h before DMEM
starvation and further treatment.

Red-conjugated antibody (Vector Laboratories, 1:300), for 4–5 h
at room temperature. After antibody removal (blocking solution,
10 min, once; PBS, 10 min, three times), slices were then
incubated with fluoroscein-conjugated avidin (Vector Laboratories, diluted 1:500 with PBS), for 1 h at room temperature. After
washing (PBS, 10 min, four times), the wet sections were placed
on slides and coverslipped with anti-fluorescence fading fluid
(Vectashield, Vector Laboratories). Control sections in which
primary antibodies were omitted showed no labeled cells. Images
of equivalent regions, 5126512 pixels, were made on a Leica
TCS SP2 AOBS spectral confocal microscope using a 1006, 1.4
numerical aperture oil-immersion objective at a 46 zoom. A
single optical section (0.8-mm thick) was taken from each tissue
section, and at least five sections per region of interest were
analyzed for each animal. All microscope settings were unchanged from section to section.
Due to the reduced intensity of PSD-95 and SYN immunostained puncta in the AS mouse, a significant number of the
weaker stained opposing puncta could not be resolved using
digital-quantification software; therefore, we chose to manually
quantify the synaptic contacts to obtain a more accurate
assessment of PSD-95/SYN contacts. PSD-95 and SYN paired
confocal images were adjusted for contrast/brightness to
optimize detection of the faintly stained PSD-immunostained
puncta and then magnified to fit the dimensions of a high
resolution flat-screen monitor (179 mm6179 mm). PSD-95immunostained puncta were first mapped onto an acetate sheet
overlay and the counted to obtain total distribution of PSD-95
puncta/mm2. The corresponding SYN-immunostained image
was then superimposed under the PSD-95 acetate template,
whereby all PSD-95/SYN contacts were then circled and
quantified. Quantification of synaptic contacts was preformed
blindly by at least three separate individuals. Data represent a
minimum of seven sets of non-overlapping images/region/
strain quantified blind. Only direct SYN/PSD-95 contacts
were counted, i.e., PSD-95 puncta in apposition to SYNimmunoreactive puncta, were then assessed with Image J for
their corresponding staining intensities by placement of a circle
32 pixels2 over each of the thresholded puncta. It is important
to note that in Image J, thresholding an image does not change
the value of the puncta intensity from the non-thresholded
image. Groups of animals were compared using a two-tailed,
two-sample equal variance t test.

Antibodies
Antibodies against Gab1 (sc-9049), PLCc1 (sc-166938), Arc (sc15325), CaMKIIa (sc-13141), Erk1/2 (sc-93), and Akt1-2 (sc8312), goat antibody against rabbit immunoglobulin G (IgG)
conjugated to horseradish peroxidase (HRP) (sc-2030), and goat
antibody against mouse IgG-HRP (sc-2031) were purchased from
Santa Cruz Biotechnology. Mouse monoclonal antibody (mAb)
against PSD-95 (clone K28/43) (MABN68) was purchased from
Millipore, rabbit monoclonal antibody against PSD-95 (cs-3450)
was purchased from Cell Signaling Tech. Mouse mAb aAntiUbe3A (E6AP) (clone Ex-8) was obtained from Enzo Life Sciences
(BML-PW0535). P-CaMKII (Thr286/287, clone 22B1) was
obtained from Cayman Chemicals and b-actin (mouse mAb)
was purchased from Sigma. P-Akt (Ser473) antibody (9271) was
used unless otherwise indicated as p-Akt (Thr308) antibody (9275);
p-GSK-3a/b (Ser9/21) antibody (9336), p-S6 ribosomal protein
(Ser235/236) antibody (2211), p-p70 S6 Kinase (Thr398) antibody
(9209), p-4E-BP1 (Ser65) antibody (9451), p-p44/42 MAPK
(Erk1/2) antibody (9102), p- CREB (Ser133) antibody (9191),
TrkB antibody (4606), and p-Trk (C35G9) Rabbit mAb (4619)
were obtained from Cell Signaling Technology.

Western Blotting Analysis and Immunoprecipitation
CGNs, SH-SY5Y cells or brain slices treated with the
appropriate stimuli were lysed with lysis buffer (200 mM NaCl
[pH 7.4], 1% Triton X-100, 10% glycerol, 0.3 mM EDTA,
0.2 mM Na3VO4, and protease inhibitor cocktail [Roche Diagnostics]). Aliquots of 40 mg of protein from each treatment were
separated by 10% SDS-PAGE and transferred onto a PVDF
membrane (Millipore). After blocking with 10% instant nonfat dry
milk for 1 h, membranes were incubated with specific antibodies
overnight at 4uC followed by incubation with secondary antibodies
(HRP-conjugated anti-rabbit or anti-mouse IgG at the appropriate
dilutions) for 1 h at room temperature. Antibody binding was
detected with the enhanced chemiluminescence (ECL) detection
system (Amersham Biosciences). Western blot results were
quantified by using Image J software (NIH) after normalization
to their individual loading controls. For IP, aliquots of 700 mg of
proteins from each sample were precleared by incubation with
20 ml of protein A/G Sepharose (beads) (Amersham) for 1 h at
4uC. Pre-cleared samples were incubated with specific antibodies
in lysis buffer overnight at 4uC. 30 ml of protein A/G beads were
added and the samples were incubated for 2 h at 4uC. The beads
were washed five times with phosphate-buffered saline (PBS) (4uC)
and once with lysis buffer, boiled, separated by 10% SDS-PAGE,
and transferred onto a PVDF membrane followed by Western
blotting analysis as described above. 40 mg of protein from each

Plasmids and RNAi Transfection
WT human Myc-DDK-tagged Arc cloned into the pCMV6
vector was obtained from OriGene and HA-E6AP cloned into
pCMV4 was from Addgene. The WT-TrkB cDNA was a gift from
Luc De Vries and Myc–PSD-95 cloned into GW1-CMV (British
Biotechnology) was a gift from Morgan Sheng. Knockdown was
performed using HUSH technology (Origene). A pRS plasmid
vector (Origene) containing shRNA that is effective against human
or mouse Ube3A (59AGGTTACCTACATCTCATACTTGCTTAA); human and mouse PSD-95 (59-GG AGA CAA GAT CCT
GGC GGT CAA CAG TGT, sh95A; and 59-AAT GGA GAA
GGA CAT TCA GGC GCA CAA GT, sh95B) were purchased
from Origene. RNA duplex oligonucleotides (RNAi) against
Ube3A (59-GUUACCUACAUCUCAUACUUGCUUUAA) or
PSD-95 (59-AGA CAA GAU CCU GGC GGU CAA CAG
UGU, sh95A; and AAT GGA GAA GGA CAU CCA GGC ACA
CAA GT, sh95B) were purchased from Integrated DNA
Technologies (IDT). Arc shRNA was generated using the
previously described sequence [10]. Plasmid transfection into
neuroblastoma SH-SY5Y cells was performed with Lipofectamine
PLOS Biology | www.plosbiology.org
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(2 mM). (B) CN2097 improves BDNF signaling in Ube3A
knockdown SH-SY5Y-TrkB cells. Upper panel: Western blot
analysis of protein lysates prepared from TrkB transfected SHSY5Y cells (SH-SY5Y-TrkB) cotransfected with scrambled control
shRNA (scRNAi) or Ube3A shRNA (48 h), treated with BDNF
(25 ng/ml) in the presence or absence of CN2097 (2 mM, 20-min
pretreatment). Expression of Ube3A, p-CaMKII, p-Akt, p-GSK,
p-S6, and CaMKII (sister gel) are shown. Knockdown of Ube3A
impeded BDNF-induced p-CaMKII, p-Akt, p-GSK, and p-S6
activation. Lower panel: Depleting Ube3A expression using
Ube3A shRNA did not alter BDNF induced pErk activation
compared to scrambled RNAi control. Akt1/2 and PSD-95 levels
were also not affected by Ube3A knockdown and serve as loading
controls. Middle right panel: Knockdown of Ube3A enhances Arc
expression in SH-SY5Y cells. SH-SY5Y-TrkB cells transfected
with scRNAi or Ube3A shRNA show increased Arc levels in
Ube3A-depleted cells, whereas PSD-95 levels were unaffected.
Lower right panel: Quantitation of the p-Akt western blot lanes
(left panel). Knockdown of Ube3A results in a significant loss of pAkt (p,0.05) and CN2097 restores p-Akt levels to control levels
(p.0.1). # indicates the column that is normalized to 1.0. (C)
Specificity of Ube3A RNAi. Expression of Ube3A restores BDNF
signaling in SH-SY5Y cells in which endogenous Ube3A was
depleted with Ube3A RNAi. Western blot analysis of protein
lysates prepared from SH-SY5Y cells transfected with TrkB (SHSY5Y-TrkB, 48 h) and the following plasmids: scrambled shRNA,
termed scRNAi; Ube3A shRNA+empty vector; Ube3A shRNA
(0.1 mg)+Ube3A cDNA, followed by BDNF treatment (25 ng/ml)
for the indicated time points. Blots were probed with antibodies
against Ube3A, p-Erk, p-Akt, Akt (sister gel), p-TrkB, and PSD-95.
(TIFF)

treatment was also utilized for Western blot as input controls. All
blots are representative of at least three independent experiments.

CN2097 Synthesis
The peptide KNYKKTEV, was cyclized between the valine (V)
and threonine (T) residues via a b-lactam alanine and linked to a
seven member linear poly-arginine tail (R7) by a disulfide bond
(CN2097: R7-CC- KNYKKT[bA]EV, MW2376) to enhance its
diffusion and uptake capacity by neurons in intact tissues. The
cyclic and poly-arginine moieties were synthesized and purified
separately and subsequently coupled. A negative control peptide
was prepared by introducing two disruptive alanine residues at the
critical 0 and 22 ring positions that comprise the critical binding
region (CN 5135). Standard fmoc-based protocols were used to
synthesize all peptides. The chemical structures were determined
using a high-resolution time-of-flight electrospray mass spectrometer. Reagents were sourced from Fisher, BA Chemicals, Berry,
Wikem, Sigma, Novabiochem, Chempep, Quanta, and RSP
amino-acids.

Statistics
A two-tailed Student’s t test was used to test for statistical
significance in electrophysiological results and for measuring
statistical significance of quantitative Western blot and imaging
analyses. GraphPad Prism data analysis software was used for
graph production and statistical analysis. Values are presented as
mean 6 SEM. Results were deemed significant where *p,0.05,
**p,0.01, and ***p,0.001.

Supporting Information
Figure S1 (A) CN2097: Design of a cell-permeable PDZ
domain-targeting macrocycle. Standard Fmoc-based protocols
[93], were used to synthesize the cyclic-peptide, CN2097,
targeting the PDZ domain of PSD-95. The peptide, KNYKKTEV, was cyclized between the Val and Thr residues via a balanine linkage and linked to a poly-arginine tail to enhance its
uptake by neurons. Also shown is a control cyclic peptide,
CN5135, having the Ala/Ala double mutation at the 0/22
positions, which knocks out binding to PDZ domains. (B) In situ
uptake of CN2097 into rat neurons. (A) Pyramidal cells located in
CA1 by 24 h following intra-ventricle injection of TMR-tagged
CN2097. (B) Similar uptake was noted in multiple populations of
rat retinal ganglion cells 6 h following intravitreal injection. (C)
Although not as robust as shown in (B), selective uptake in retinal
ganglion cells was noted 8 h following an intravenous injection of
FITC-tagged CN2097, indicating that the peptide mimic is not
only capable of crossing meningeal membrane barriers and
selectively taken up by neurons, but also has the ability to cross
the blood/brain barrier.
(TIFF)

Figure S3 (A) The input lanes of lysate used for WT and AS
slices TrkB-coIP westerns shown in Figure 3A (upper panel) show
the expression level of TrkB, PLCc, PSD-95, and Gab1. CN,
CN2097. (B) The input lanes of lysate from fresh hippocampus
(hippo) and cerebellum (CB) of WT and AS, used for TrkB co-IP
Western blots shown in Figure 3B, show the expression level of
TrkB, PSD-95, Ube3A, and Akt1/2. (C) Knockdown of PSD-95 in
SH-SY5Y-TrkB cells disrupt CN2097 enhancement of BDNF
signaling. Upper panel: Western blot analysis of protein lysates
prepared from TrkB transfected SH-SY5Y cells (SH-SY5Y-TrkB,
48 h) cotransfected with scrambled control shRNA (scRNAi) or
PSD-95 shRNA (sh95A), treated with BDNF (25 ng/ml) in the
presence or absence of CN2097 (2 mM, 20-min pretreatment).
The expression level of PSD-95 and phosphorylation of Erk, TrkB,
Akt, 4E-BP1, and S6 were detected. TrkB was generated from an
identically loaded sister gel. The RNAi mediated knockdown of
PSD-95 reduced expression to 14.1%63.5% compared to
untransfected cells, and impeded BDNF-induced p-Akt, p-4EBP1, and p-S6 induction as compared with cells transfected with
scRNAi. Furthermore, CN2097 could not rescue BDNF signaling
in the PSD-95 depleted cells. Lower left panel: Quantitation of
Western blot data for p-Akt. CN2097 significantly enhances p-Akt
signaling (**p,0.01). Knockdown of PSD-95 blocks p-Akt
signaling and prevents CN2097 rescue of signaling (p.0.1). #
indicates column that is normalized to 1.0; ns, not significant.
Lower right panel: PSD-95 RNAi knockdown in CGNs does not
change the levels of TrkB expression or inhibit BDNF-induced
TrkB activation. Western blot analysis of PSD-95, TrkB and ERK
expression, and phosphorylation of Erk and TrkB. Primary mouse
CGNs (p5) transfected with scrambled control (scRNAi, 200 nM,
24 h) or PSD-95 siRNA oligonucleotides (sh95A; 200 nM, 24 h)
were serum starved and treated with BDNF (25 ng/ml, 10 min).
Numbers below selected rows represent normalized optical density

(A) Western blots showing that CN2097 alone does
not stimulate Erk, Akt, or CaMKII signaling in AS brain slices,
and that the control compound CN5135 does not enhance BDNF
signaling over levels produced by BDNF alone in WT slices. WT
slices exposed to CN2097, show a 2- to 3-fold enhancement of
BDNF-induced p-Akt and p-CaMKII signaling (p,0.01), over
slices treated with BDNF alone. The level of basal p-CaMKIIa
(phospho-Thr286) is enhanced in AS untreated slices compared to
WT (09, lanes indicated with an #). Blots were probed for p-Erk1/
2, p-CaMKII, p-Akt-S473, and Akt loading control. WT slices
were stimulated with BDNF (50 ng/ml) in the presence or absence
of CN2097 (2 mM), or the control compound CN5135 (2 mM; 30min pretreatment). AS brain slices were treated with CN2097
Figure S2
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(OD) values. (D) Quantitation for Figure 3D. Summary data for
the 20-min time point showing p-CaMKII and p-Akt (T308) but
not p-Erk were significantly enhanced in cells overexpressing PSD95 compared to control SH-SY5Y-TrkB cells (*p,0.05). (E)
Quantitation for Figure 3E. Knockdown of Ube3A resulted in a
significant decrease in p-Akt (T308) and p-CaMKII levels
(*p,0.05), while overexpression of PSD-95 enhanced both p-Akt
and p-CaMKII (*p,0.05) in Ube3A knockdown cells. (F)
Specificity of PSD-95 RNAi. Left panel: Specificity of sh95A.
Western blot analysis of protein lysates prepared from TrkB
transfected SH-SY5Y cells (SH-SY5Y-TrkB, 48 h), co-transfected
with the following plasmids: PSD-95 sh95A+empty vector; PSD95-sh95A+rat PSD-95, followed by BDNF treatment (25 ng/ml)
for 20 min. PSD-95 shRNA transfected cells show a dramatic
reduction in PSD-95 levels compared with control cells (09),
resulting in a very low p-Akt, but normal p-Erk signal, in response
to BDNF. Transfection of RNAi resistant PSD-95 cDNA restored
BDNF-induced pAkt at 209. Blots were probed with antibodies
against Ube3A and Akt as loading controls. Right panel: PSD-95
knockdown by sh95B siRNA disrupts BDNF signaling. Western
blot analysis of protein lysates prepared from primary CGNs
showing PSD-95 expression and BDNF-induced Akt and S6
activation. Akt1/2 was detected as a loading control. Primary rat
CGNs were prepared from newborn Sprague-Dawley pups (p5),
transfected with scrambled control (scRNAi, 200 nM, 24 h) or
PSD-95 siRNA oligonucleotides (sh95B; 200 nM, 24 h), serum
starved and treated with BDNF (25 ng/ml) for 7 and 15 min. (G)
SAP97, SAP102, or Chapsyn110 do not enhance BDNF signaling
in SH-SY5Y-TrkB cells. Western blot analysis of protein lysates
prepared from TrkB transfected SH-SY5Y cells (SH-SY5Y-TrkB,
48 h), co-transfected with the following plasmids: GFP, SAP97,
SAP102 or Chapsyn 110 (0.5 mg/ml each, 48 h), serum starved
and treated with BDNF (25 ng/ml), show that none of these
MAGUKS enhanced BDNF-induced pAkt or p-S6. Western blots
were probed with antibodies against p-Akt and b-actin as loading
control. p-Erk and p-S6 were generated from an identically loaded
sister gel. (H) PSD-95 knockdown does not affect IGF signaling in
WT-CGN. Western blot analysis of protein lysates prepared from
WT CGN (p5), transfected with scrambled control (200 nM, 24 h)
or PSD-95 siRNA oligonucleotides (sh95A; 200 nM, 24 h), serum
starved and treated with IGF (25 ng/ml), show that depletion of
PSD-95 does not impede IGF-induced p-Akt activation. In
addition, CN2097 does not enhance IGF-p-Akt activation in
CGN cells transfected with scRNAi. Ube3A and b-actin were
generated from an identically loaded sister gel.
(TIFF)

min pretreatment). Western blots were probed with antibodies to Arc,
Myc, PSD-95, and TrkB. Bar graph: Quantitation of the association
of Arc and PSD-95 (n = 3) represented in the upper panel. Arc
transfection resulted in a significant increase in its association with
PSD-95 (**p,0.01), and disrupted TrkB binding. CN2097 prevented
Arc association with PSD-95 (**p,0.01), and restored TrkB binding
to WT levels (p,0.1). Middle lower right panel: The input lanes for
each treatment showing equal expression and loading of PSD-95,
Akt, and b-actin. Lower right panel: Quantitation of Figure 4B
showing that Arc expression results in significantly lower BDNFinduced p-Akt and p-CaMKII (p,0.05). BDNF-signaling in SHSY5Y-TrkB cells co-transfected with either null-vector or Arc-myc
containing vector (acquired from Western blots shown in Figure 4,
n = 3). Results show that CN2097 enhances BDNF p-CaMKII and
pAkt (*p,0.05). (C) Western blot analysis showing that Arc
knockdown restores BDNF signaling in cells expressing a dominant
negative Ube3A (E6AP C833A). SH-SY5Y-TrkB cells and SHSY5Y-TrkB cells transfected (48 h) with a dominant negative Ube3A
(E6AP C833A) [65] +/2 Arc shRNA (0.1 mg), were treated with
BDNF (25 ng/ml) for indicated time points. Results show that
interfering with Ube3A function elevates Arc, which in turn reduces
BDNF activation of p-Akt signaling when compared to SH-SY5YTrkB control cells (p,0.001; for both S473 and T308 quantitated at
the 10-min time point). Suppressing Arc in the DN-Ube3A cells
restored BDNF-induced p-Akt to control levels (p.0.1 for both S473
and T308 at the 10-min time point). Note that BDNF-signaling of pErk1/2 was not affected. Western blots were probed with antibodies
to Arc, p-Akt (S473 and T308), Akt (sister gel), p-Erk1/2, and the
loading control Erk1/2. All blots are representative of at least three
independent experiments.
(TIFF)
Figure S5 PSD-95 (green) and SYN (red) antibodies were used
to stain synapses in the hippocampus. PSD-95 and SYN stained
puncta quantified using image J are displayed for CA1-SR (A–D),
CA3 (E–H), and DG (I–L) and showing relative distributions of
stained puncta and the average staining intensities of the identified
puncta between WT and AS mice. Results show that in CA1-SR
there is a significant decline in the relative number of PSD-95
stained puncta in the AS mouse (A), whereas no differences were
recorded in CA3 (E) and in the DG (I). Similarly, there was a
significant decline in the number of SYN-puncta noted in CA1 (B)
and also in CA3 (F) but not in the DG (J). In comparing the
average relative staining intensities of the captured puncta, there
were no differences noted between WT and AS for PSD-95 for all
three regions sampled (C, G, and K); however, significant
differences in the average staining intensity for SYN were recorded
in CA1 (D) and CA3 (H), but not in the DG (L). Immunostained
sections were imaged on a confocal microscope using 1006
objective and a 46 zoom. Scale bar = 7.5 mm.
(TIFF)

Figure S4 (A) Upper panel: quantitation for the association of Arc

and PSD-95 in Figure 4A. AS mice have significantly greater levels of
Arc associated with PSD-95 than their WT counterparts (*p,0.05)
and CN2097 disrupts this (*p,0.05). Middle panel: Arc and PSD-95
show greater association in AS mice after normalization of the input
of Arc. Co-IP assay with an antibody to Arc from lysates prepared
from both WT (1 mg lysate) and AS (0.33 mg lysate; note AS Arc
input is 0.85 of WT). Western blots were probed with antibodies to
PSD-95 show that the association of PSD-95 with Arc is significantly
greater in the AS mouse (p,0.05). Lower panel shows the input levels
of Arc, Ube3A and PSD-95 detected in lysates normalized for Arc.
Numbers below selected rows represent normalized optical density
(OD) values. (B) Arc associates with PSD-95 to disrupt TrkB-PSD-95
association. Upper panel: Co-IP assay with an antibody to PSD-95
from lysates prepared from TrkB transfected SH-SY5Y cells (SHSY5Y-TrkB, 48 h) cotransfected with control empty vector or Arcmyc-tagged cDNA. Cells were untreated or stimulated with BDNF
(25 ng/ml, 10 min) in the presence or absence of CN2097 (2 mM, 20PLOS Biology | www.plosbiology.org
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